The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...
Guidance for 2025 projects total net revenue between $955M and $1.25B, reflecting a decline from 2024 due to erosion in SUBOXONE Film net revenue and the discontinuation of PERSERIS. SUBLOCADE’s 2025 ...
Canoga Park, California, June 02, 2025 (GLOBE NEWSWIRE) -- Aegis Treatment Centers, part of the Pinnacle Treatment Centers Family of Companies, a leader in providing evidence-based care for ...
CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results